The Enterprise Value as of June 2026 (TTM) for Supernus Pharmaceuticals, Inc. (SUPN) is 2.43B

According to Supernus Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 2.43B. This represents a change of -1.05% compared to the average of 2.46B of the last 4 quarters.

Supernus Pharmaceuticals, Inc. (SUPN) Historical Enterprise Value (quarterly & annually)

How has SUPN Enterprise Value performed in the past?

The mean historical Enterprise Value of Supernus Pharmaceuticals, Inc. over the last ten years is 1.81B. The current 2.43B Enterprise Value has changed 13.33% with respect to the historical average. Over the past ten years (40 quarters), SUPN's Enterprise Value was at its highest in in the June 2018 quarter at 3.39B. The Enterprise Value was at its lowest in in the June 2016 quarter at 952.33M.

Supernus Pharmaceuticals, Inc. (SUPN) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Supernus Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Supernus Pharmaceuticals, Inc. (SUPN) Average Enterprise Value

How has SUPN Enterprise Value performed in the past?

The current Enterprise Value of Supernus Pharmaceuticals, Inc. (SUPN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Supernus Pharmaceuticals, Inc. (SUPN) Enterprise Value vs. Peers

How is SUPN’s Enterprise Value compared to its peers?

Supernus Pharmaceuticals, Inc.’s Enterprise Value is greater than HUTCHMED (China) Limited (1.91B), less than Perrigo Company plc (4.97B), less than Xenon Pharmaceuticals Inc. (3.57B), less than Indivior Pharmaceuticals Inc (5.14B), less than Bausch Health Companies Inc. (21.39B), less than Amneal Pharmaceuticals, Inc. (7.67B), less than Lantheus Holdings, Inc. (6.31B), less than Centessa Pharmaceuticals plc (6.09B), less than GRAIL, Inc. (2.55B), less than CG Oncology, Inc. Common stock (5.23B),

Build a custom stock screener for Supernus Pharmaceuticals, Inc. (SUPN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Supernus Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Supernus Pharmaceuticals, Inc. (SUPN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Supernus Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.